Cagrilintide (AM833 / NN9838) is a synthetic long-acting analogue of amylin, developed by Novo Nordisk and currently under Phase 3 clinical investigation. It acts as a non-selective agonist of amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR), primarily targeting neuronal populations in the dorsal vagal complex of the brainstem and the hypothalamus to modulate satiety and reduce food intake.
Its structure is built on a 37-amino acid backbone similar to pramlintide, with key substitutions (N14E, V17R, P37Y) and N-terminal acylation using a C20 eicosanedioic fatty diacid attached via a gamma-glutamic acid linker — the same lipid architecture that extends semaglutide's half-life. This design yields an elimination half-life of 159–195 hours, enabling once-weekly subcutaneous dosing.
In Phase 2 monotherapy (4.5 mg dose), cagrilintide produced 10.8% weight loss over 26 weeks, outperforming liraglutide 3.0 mg. This high-purity research chemical (≥99% HPLC) is supplied by BIOTOPEP as a lyophilized powder, strictly for scientific and laboratory use only.
Lyophilized powder: Long-term storage at -20 °C (24 months). Short-term between 2 and 8 °C (3 months). Store under inert atmosphere (nitrogen), protected from moisture and light.
Reconstituted solution: Must be stored at 2–8 °C. Stable for up to 28 days after reconstitution with bacteriostatic water.
Do not freeze after reconstitution. Mix gently by slow rotation. Keep strictly away from light, UV, and humidity. Keep out of reach of children.